Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mustafa Özgüroǧlu"'
Autor:
Hatice Bolek, Cagatay Arslan, Mert Basaran, İrfan Cicin, Mustafa Ozguroglu, Deniz Tural, Yüksel Ürün
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEDurable complete response rates for metastatic renal cell carcinoma (mRCC) and metastatic bladder cancer (mBC) are low despite new therapy. Palliative care focuses on life extension and quality of life (QoL), not cure. This study aims to inves
Externí odkaz:
https://doaj.org/article/cb5cd9d0b8f74576a1727fb5374b5887
Autor:
Johan F. Vansteenkiste, MD, PhD, Jarushka Naidoo, MB, BCH, MHS, Corinne Faivre-Finn, MD, PhD, Mustafa Özgüroğlu, MD, Augusto Villegas, MD, Davey Daniel, MD, Shuji Murakami, MD, Rina Hui, M.B.B.S., PhD, Ki Hyeong Lee, MD, Byoung Chul Cho, MD, PhD, Kaoru Kubota, MD, PhD, Helen Broadhurst, MSc, Catherine Wadsworth, BVSc, Michael Newton, PharmD, Piruntha Thiyagarajah, MD, Scott J. Antonia, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100638- (2024)
Introduction: In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.00251) in patients with unresectable stage III NSCLC and no progression a
Externí odkaz:
https://doaj.org/article/86197b668ce247a6aed1dbb164a76e9d
Autor:
Mustafa Ozguroglu, Saadettin Kilickap, Igor Bondarenko, Ahmet Sezer, Mahmut Gümüş, Miranda Gogishvili, Xuanyao He, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d567674c409344d1a377a09a1890d0a4
Autor:
Kohei Shitara, Kei Muro, Razvan Cristescu, Michael Nebozhyn, Andrey Loboda, Hyun Cheol Chung, Wasat Mansoor, Mustafa Ozguroglu, Mario Mandala, Maria Di Bartolomeo, Christian Caglevic, Julie Kobie, Min-Hee Ryu, Z Alexander Cao, Tomasz Olesinski, Eray Goekkurt, Raymond S McDermott, Zev A Wainberg, Chie-Schin Shih
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background In the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gas
Externí odkaz:
https://doaj.org/article/47cdd46fe09d4f619548677a08c6eb63
Autor:
İrfan Cicin, Mohammed Oukkal, Hassen Mahfouf, Amel Mezlini, Blaha Larbaoui, Slim Ben Ahmed, Hassan Errihani, Khalid Alsaleh, Rhizlane Belbaraka, Perran Fulden Yumuk, Burce Goktas, Mustafa Özgüroğlu
Publikováno v:
European Journal of Breast Health, Vol 18, Iss 1, Pp 63-73 (2022)
Objective:This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor recept
Externí odkaz:
https://doaj.org/article/44aa8ae6d88d49109eadb32a73987363
Autor:
Yuanbin Chen, MD, PhD, Luis Paz-Ares, MD, PhD, Niels Reinmuth, MD, PhD, Marina Chiara Garassino, MD, Galina Statsenko, MD, Maximilian J. Hochmair, MD, Mustafa Özgüroğlu, MD, PhD, Francesco Verderame, MD, Libor Havel, MD, György Losonczy, MD, PhD, Nikolay V. Conev, MD, PhD, Katsuyuki Hotta, MD, PhD, MPH, Jun Ho Ji, MD, PhD, Stuart Spencer, MSc, Tapashi Dalvi, PhD, MPH, Haiyi Jiang, MD, Jonathan W. Goldman, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100330- (2022)
Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) sign
Externí odkaz:
https://doaj.org/article/1c079ba625de443f80bdb5548364cf07
Autor:
Düriye Sıla Karagöz Özen, Mehmet Akif Öztürk, Fatih Selcukbiricik, Sinem Nihal Esatoglu, Zeynep Hande Turna, Pınar Beyaz, Sergülen Dervisoglu, Mustafa Özgüroglu
Publikováno v:
Case Reports in Oncology, Vol 6, Iss 1, Pp 224-228 (2013)
Primary cardiac osteosarcomas are uncommon tumors. They have an aggressive biology and hence poor prognosis. This report describes a 23-year-old male patient who was referred to our hospital with chest pain. Echocardiography showed a left atrial mass
Externí odkaz:
https://doaj.org/article/b0d1251aed06478c96f912fa1c9da437
Autor:
Özlem Yetmen, Didem Çolpan Öksüz, Fuat Demirkıran, Mustafa Özgüroğlu, Zerrin Calay, Gülyüz Atkovar, İsmet Sahinler
Publikováno v:
European Journal of Breast Health, Vol 8, Iss 2, Pp 92-96 (2012)
Background:Metastasis to the breast from cervical carcinoma is rarely seen.Case:A 34-year-old woman with FIGO stage III-B cervical carcinoma received potentially curative chemoradiotherapy following which, there was residual tumor. One month later, s
Externí odkaz:
https://doaj.org/article/aaf7fe6011614edeb607fe861c3380fc
Autor:
Seniz Ongoren Aydin, Ahmet Emre Eskazan, Hilal Aki, Mustafa Ozguroglu, Zafer Baslar, Teoman Soysal
Publikováno v:
Case Reports in Oncology, Vol 4, Iss 3, Pp 439-444 (2011)
Hairy cell leukemia (HCL) is an uncommon chronic lymphoproliferative disorder and accounts for around 2% of all forms of leukemias. The association of HCL with other neoplasms, mainly non-Hodgkin’s lymphomas, is well known. However, the simultaneou
Externí odkaz:
https://doaj.org/article/1ebd9f2102f34936af9b7b793b35f1d7
Autor:
Salih Pekmezci, Kaya Saribeyoglu, Erman Aytac, Macit Arvas, Fuat Demirkiran, Mustafa Ozguroglu
Publikováno v:
Asian Journal of Surgery, Vol 33, Iss 2, Pp 83-88 (2010)
Few studies have been published on liver resection alone or in combination with cytoreductive surgery for liver metastases of ovarian carcinoma. Methods: Eight patients who underwent liver resection for metastasis of ovarian cancer were included in t
Externí odkaz:
https://doaj.org/article/5003f713cad247129090fd4294a0560e